Zydus Cadila receives two product approvals from USFDA

15 Sep 2017 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Modafinil tablets USP, 100 mg and 200 mg. Modafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnoea or shift work disorder. The sales of Modafinil tablets USP are estimated at $148.66 million, as per IMS Health.

The group also received the tentative approval for Solifenacin Succinate tablets in strengths of 5 mg and 10 mg. Solifenacin Succinate tablets are indicated for the treatment of overactive bladder associated with symptoms of urinary incontinence and urinary frequency. The sales of Solifenacin Succinate tablets are estimated at $1.04 billion, as per IMS Health.

Both the drugs will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Share Price

929.05 6.60 (0.72%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×